+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Somatostatin Analogs"

Somatostatin Analogs Market - Global Forecast 2025-2032 - Product Thumbnail Image

Somatostatin Analogs Market - Global Forecast 2025-2032

  • Report
  • October 2025
  • 188 Pages
  • Global
From
Somatostatin Analogs - Global Strategic Business Report - Product Thumbnail Image

Somatostatin Analogs - Global Strategic Business Report

  • Report
  • October 2025
  • 280 Pages
  • Global
From
Somatostatin Analogs Market Report 2025 - Product Thumbnail Image

Somatostatin Analogs Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
From
From
From
From
Acromegaly Treatment Market - Global Forecast 2025-2032 - Product Thumbnail Image

Acromegaly Treatment Market - Global Forecast 2025-2032

  • Report
  • October 2025
  • 189 Pages
  • Global
From
From
From
From
From
From
Acromegaly Treatment - Global Strategic Business Report - Product Thumbnail Image

Acromegaly Treatment - Global Strategic Business Report

  • Report
  • October 2025
  • 297 Pages
  • Global
From
From
From
Loading Indicator

Somatostatin Analogs are a class of drugs used in the treatment of oncology. They are used to inhibit the release of hormones, such as growth hormone, which can be overproduced in certain types of cancer. Somatostatin Analogs are used to treat a variety of cancers, including neuroendocrine tumors, carcinoid tumors, and pancreatic islet cell tumors. They are also used to treat acromegaly, a condition caused by excessive growth hormone production. Somatostatin Analogs are administered either intravenously or subcutaneously, depending on the type of cancer being treated. The Somatostatin Analogs market is a rapidly growing segment of the oncology drugs market. It is driven by the increasing prevalence of cancer, as well as the development of new and improved drugs. The market is expected to continue to grow in the coming years, as more drugs are developed and approved for use. Some of the major companies in the Somatostatin Analogs market include Novartis, Pfizer, Merck, and Sanofi. Show Less Read more